CA3110138A1 - Novel cancer immunotherapy antibody compositions - Google Patents

Novel cancer immunotherapy antibody compositions Download PDF

Info

Publication number
CA3110138A1
CA3110138A1 CA3110138A CA3110138A CA3110138A1 CA 3110138 A1 CA3110138 A1 CA 3110138A1 CA 3110138 A CA3110138 A CA 3110138A CA 3110138 A CA3110138 A CA 3110138A CA 3110138 A1 CA3110138 A1 CA 3110138A1
Authority
CA
Canada
Prior art keywords
seq
antibody
antigen
chain variable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3110138A
Other languages
English (en)
French (fr)
Inventor
Chiang J. Li
Shyam UNNIRAMAN
Hannah BADER
Mithilesh JHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1Globe Biomedical Co Ltd
1Globe Health Institute LLC
Original Assignee
1Globe Biomedical Co Ltd
1Globe Health Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd, 1Globe Health Institute LLC filed Critical 1Globe Biomedical Co Ltd
Publication of CA3110138A1 publication Critical patent/CA3110138A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3110138A 2018-08-20 2019-08-20 Novel cancer immunotherapy antibody compositions Pending CA3110138A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720015P 2018-08-20 2018-08-20
US62/720,015 2018-08-20
PCT/CN2019/101659 WO2020038379A1 (en) 2018-08-20 2019-08-20 Novel cancer immunotherapy antibody compositions

Publications (1)

Publication Number Publication Date
CA3110138A1 true CA3110138A1 (en) 2020-02-27

Family

ID=69591356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3110138A Pending CA3110138A1 (en) 2018-08-20 2019-08-20 Novel cancer immunotherapy antibody compositions

Country Status (12)

Country Link
US (1) US12391758B2 (https=)
EP (1) EP3841126A4 (https=)
JP (1) JP7488534B2 (https=)
KR (1) KR20210046725A (https=)
CN (2) CN116410320A (https=)
AU (1) AU2019324388A1 (https=)
BR (1) BR112021003182A2 (https=)
CA (1) CA3110138A1 (https=)
MX (1) MX2021002077A (https=)
SG (1) SG11202101757QA (https=)
TW (1) TW202016150A (https=)
WO (1) WO2020038379A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023187460A1 (en) * 2022-04-01 2023-10-05 Mabtree Biologics Ag Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
CN118930652B (zh) * 2024-07-29 2025-03-11 北京肿瘤医院(北京大学肿瘤医院) 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
KR101814408B1 (ko) * 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) * 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CA2979219A1 (en) 2015-03-10 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind psma
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EA037855B1 (ru) * 2016-01-29 2021-05-27 Сорренто Терапьютикс, Инк. Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1
CN108350082B (zh) * 2016-06-13 2021-09-24 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
CN106496327B (zh) * 2016-11-18 2019-01-15 昆山百尔泰生物科技有限公司 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
CN108239149B (zh) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
CN107973854B (zh) * 2017-12-11 2021-05-04 苏州银河生物医药有限公司 Pdl1单克隆抗体及其应用
US12378295B2 (en) * 2018-10-29 2025-08-05 1Globe Biomedical Co., Ltd. Rationally designed protein compositions

Also Published As

Publication number Publication date
US20210332138A1 (en) 2021-10-28
JP2021534750A (ja) 2021-12-16
WO2020038379A1 (en) 2020-02-27
EP3841126A4 (en) 2022-08-10
CN112839963B (zh) 2023-02-10
US12391758B2 (en) 2025-08-19
BR112021003182A2 (pt) 2021-05-11
CN116063519A (zh) 2023-05-05
MX2021002077A (es) 2021-05-27
CN116410320A (zh) 2023-07-11
EP3841126A1 (en) 2021-06-30
TW202016150A (zh) 2020-05-01
AU2019324388A1 (en) 2021-03-18
SG11202101757QA (en) 2021-03-30
JP7488534B2 (ja) 2024-05-22
CN112839963A (zh) 2021-05-25
KR20210046725A (ko) 2021-04-28

Similar Documents

Publication Publication Date Title
US10973915B2 (en) Anti-PD-1 antibodies and uses thereof
CN111094350B (zh) 调节由细胞表达的生物活性的抗体
US20180194862A1 (en) Bispecific binding proteins
JP7727086B2 (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
EP3753951A1 (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN113880952A (zh) 自然杀伤细胞接合抗体融合构建体
CN107428833A (zh) Ror1特异性抗体和嵌合抗原受体
EA036779B1 (ru) Моноклональное антитело к pd-1 и способ его получения
JP7822576B2 (ja) 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
JP7352007B2 (ja) ヒト化抗ｖｅｇｆモノクローナル抗体
CN120712284A (zh) 抗pd-1抗体抗原结合域和免疫偶联物
JP7802282B2 (ja) 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体
CN117355540A (zh) 抗cd137抗体和使用方法
US12391758B2 (en) Anti-PD-L1 cancer immunotherapy antibodies
CN106062193A (zh) 新型与人tlr2及人tlr4结合的双特异性抗体
CN120424213A (zh) 特异性结合pd-1的单克隆抗体及其医药用途
CN116063519B (zh) 新型癌症免疫治疗抗体组合物
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
HK40047112A (en) Novel cancer immunotherapy antibody compositions
HK40089568A (zh) 新型癌症免疫治疗抗体组合物
HK40089569A (zh) 新型癌症免疫治疗抗体组合物
TW202600594A (zh) 結合構築體(一)
KR20260035361A (ko) 폴리오바이러스 수용체에 대한 항체 및 이의 용도
JP2026069499A (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
CN121591871A (zh) 一种抗补体蛋白c5抗体或其抗原结合片段及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240808